Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.

$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.

$Ligand Pharmaceuticals (LGND.US)$gained 23% to $91.68 following upbeat quarterly earnings.

$Beam Therapeutics (BEAM.US)$gained 26.8% to $45.43 after the company reported fourth-quarter financial results.

$Hims & Hers Health (HIMS.US)$climbed 33.6% to $13.70 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.

$AdaptHealth (AHCO.US)$jumped 29.6% to $9.89 following fourth-quarter results.

$BeiGene (BGNE.US)$climbed just 6.91%.

$Tarsus Pharmaceuticals (TARS.US)$gained 15%

$Denali Therapeutics (DNLI.US)$gained 17.6% to $19.87 following quarterly results.

$National Vision (EYE.US)$rose 17.6% to $23.48 following strong results.

$TransMedics (TMDX.US)$gained 9.5% to $85.14 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.

$Minerva Neurosciences (NERV.US)$shares dropped 58% to $2.84 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

$Thoughtworks (TWKS.US)$were down 35% to $2.9950 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.

$NRX Pharmaceuticals (NRXP.US)$was down, falling 31% to $0.2930 after the company announced the pricing of $1.5 million underwritten public offering of common stock for $0.30/share together with investor commitment for an additional $1 million.